PharmaEssentia Corporation announced that China National Medical Products Administration (NMPA) approved the marketing authorization application of Ropeginterferon alfa-2b for adult patients with PV who have had inadequate response to HU on June 28, 2024, and the Company has officially received the drug registration certificate on July 5, 2024. PharmaEssentia will initiate the sales and marketing activities for Ropeginterferon alfa-2b in China as per the launch plan. Accumulated investment expenditure incurred: In consideration of the future marketing strategy and to protect the rights of the company and investors, no public disclosure will be made for the time being.

Ropeginterferon alfa-2b is an innovative monopegylated, long-acting interferon invented and manufactured by PharmaEssentia. Ropeginterferon alfa-2b is approved to treat adult patients with Polycythemia Vera (PV) in around 40 countries worldwide, including major markets such as the United States, Japan, China and European Union.